Section 3 of 6
Product information and disease description
251 evidence topics · 76 sources
Product description
Phase of product development
Summary: regulatory status in the United States and the European Union
The FDA approved Atebrioz (zilurgisertib) tablets on September 25, 2026, one day before the September 26, 2026 PDUFA target action date, to reduce the volume of total new heterotopic ossification in adults and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva. The NDA had been accepted with Priority Review by May 2026 and was based on Cohort 1 of the Phase 2 PROGRESS study, whose primary endpoint did not reach statistical significance; the NDA was supported by secondary endpoints. Zilurgisertib holds FDA Fast Track and orphan drug designations, and the FDA issued a Rare Pediatric Disease Priority Review Voucher to Incyte at approval. Incyte developed zilurgisertib and licensed worldwide development and commercialization rights to Mirum Pharmaceuticals in April 2026. In the European Union, zilurgisertib received orphan designation EU/3/25/3119 on August 22, 2025, and a marketing authorization application is under review by the EMA. The U.S. commercial launch began in October 2026.
FDA approval
| Field | Quoted record |
|---|---|
| Drug name | “Atebrioz” |
| Active ingredient | “zilurgisertib” |
| Approval date | “9/25/2026” |
| FDA-approved use on approval date | “To reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva” |
Regulatory status: Approved; NDA accepted by May 2026 and approved September 2026
| Action date | Submission | Action type |
|---|---|---|
| “09/25/2026” | “ORIG-1” | “Approval” |
Launch: Launched October 2026
Primary endpoint of the pivotal study and the basis of the NDA
Fast Track, Priority Review, and Orphan Drug designations
Breakthrough Therapy designation
No evidence found.
Rare Pediatric Disease Priority Review Voucher
License of worldwide rights from Incyte to Mirum Pharmaceuticals
European Union orphan designation
| Designation field | Quoted record |
|---|---|
| Active substance | “zilurgisertib” |
| Intended use | “Treatment of fibrodysplasia ossificans progressiva” |
| Orphan designation status | “Positive” |
| EU designation number | “EU/3/25/3119” |
| Date of designation | “22/08/2025” |
| Sponsor | “Incyte Biosciences Distribution B.V.” |
European Union marketing authorization application
Ongoing development in children younger than 12 years
Earlier development for anemia
“The oral, potent, and highly selective activin receptor-like kinase 2 (ALK2) inhibitor zilurgisertib (INCB000928) is in development as a treatment for fibrodysplasia ossificans progressiva (FOP), and for anemia due to myelofibrosis, myelodysplastic syndromes, and multiple myeloma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Product information
Generic, brand name and therapeutic class of product
Manufacturer: Mirum Pharmaceuticals
Brand name, generic name, and therapeutic class
Dosage forms and strengths
Package presentation and storage
Average sales price and wholesale acquisition cost
Summary: estimated monthly and annual cost
- Price basis: analyst estimate. No wholesale acquisition cost, list price, or average sales price for Atebrioz had been published as of 17 November 2026, although the U.S. launch began in October 2026. The estimate uses the annual cost of about $750,000 estimated by a Citizens analyst and reported by Reuters, and assumes that this figure applies to the recommended dosage of 100 mg once daily; it carries the uncertainty of an analyst estimate and is to be replaced when Mirum Pharmaceuticals publishes a price.
- Dosing basis: 100 mg orally once daily, taken as four 25 mg tablets, the only marketed strength; one bottle of 120 tablets is a 30-day supply at this dosage.
- Base case: $750,000 per year ÷ 12 = $62,500 per month. The implied daily cost is $750,000 ÷ 365 days = $2,055 per day ($514 per tablet), or $61,644 per bottle of 120 tablets.
- Range: $375,000 to $750,000 per year ($31,250 to $62,500 per month). The low value is the 50 mg once-daily dosage (two tablets): $750,000 × 2 ÷ 4 = $375,000 per year; ÷ 12 = $31,250 per month.
- Rationale for the range: the label reduces the dosage to 50 mg once daily with a strong CYP3A4 inhibitor and makes no change with a mild or moderate inhibitor; cost is assumed proportional to the number of 25 mg tablets because one strength is marketed. Section 2 of the label states no other dose modification, so renal or hepatic impairment and adverse reactions do not change the estimate.
- Scope: drug acquisition cost at list price, excluding administration, dispensing, markups, rebates, and patient cost sharing.
Summary: announced, estimated, and comparator prices
As of 17 November 2026, Mirum Pharmaceuticals had published no wholesale acquisition cost, list price, or average sales price for Atebrioz; at approval the company stated that it would announce the price at the U.S. launch, which began in October 2026. The only published price figure is an estimate of about $750,000 per year attributed by Reuters to a named Citizens analyst. The United Kingdom horizon-scanning briefing of July 2025 recorded the cost as not yet known. For the two other FDA-approved FOP therapies, Ipsen stated an average U.S. list price for Sohonos of $624,000 per year at its 2023 approval, and Regeneron stated an average annual U.S. list price for Pasatru of about $1.4 million, with a range of $693,000 to $2.1 million by dose and body weight. In the 2023 Canadian review, the submitted price of palovarotene was $324.22 (Canadian) per mg, corresponding to about $622,373 per year for patients younger than 14 years and $1,022,894 per year for patients aged 14 years and older.
United States wholesale acquisition cost and average sales price of zilurgisertib
Analyst estimate of the annual price of zilurgisertib
Estimated cost in the United Kingdom horizon scan
Comparator list price: Sohonos (palovarotene) in the United States
Comparator list price: Pasatru (garetosmab-grts) in the United States
Comparator price in Canada: palovarotene submitted price and annual cost
American hospital formulary service (AHFS), or other drug classification
American Hospital Formulary Service classification and WHO Anatomical Therapeutic Chemical code
No evidence found.
Pharmacologic class stated in the prescribing information
Indication
Definition of total new heterotopic ossification volume in the label
Pharmacology
Mechanism of action
Kinase selectivity in preclinical characterization
“Here we describe the discovery and preclinical characterization of zilurgisertib, a novel small-molecule inhibitor of ALK2 kinase with high biochemical and cellular potency, selectivity over other BMP and TGFβ signaling receptor kinases, and excellent oral bioavailability in preclinical species.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Biochemical selectivity of zilurgisertib against related BMP and TGFβ type I receptor kinases
| Kinase | IC50 (μM) | Selectivity ratio (over ALK2 FOP) |
|---|---|---|
| ALK2 FOP (ACVR1-R206H) | “0.019”View highlighted excerpt for this quote | “−”View highlighted excerpt for this quote |
| ALK2 wild-type (ACVR1) | “0.021”View highlighted excerpt for this quote | “1.1”View highlighted excerpt for this quote |
| ALK1 (ACVRL1) | “0.31”View highlighted excerpt for this quote | “16”View highlighted excerpt for this quote |
| ALK3 (BMPR1A) | “0.92”View highlighted excerpt for this quote | “48”View highlighted excerpt for this quote |
| ALK6 (BMPR1B) | “3.00”View highlighted excerpt for this quote | “158”View highlighted excerpt for this quote |
| ALK5 (TGFBR1) | “5.80”View highlighted excerpt for this quote | “305”View highlighted excerpt for this quote |
“We were especially intrigued by the exquisitely high selectivity over ALK5, as the inhibition of ALK5 mediated TGFβ signaling was associated with severe adverse cardiac findings.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The lower observed selectivity over ALK1 and ALK3 is consistent with previous reports highlighting the low differences in protein sequence homology between those BMP receptors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The clinical safety of inhibiting ALK1, ALK3, and ALK6 is still under investigation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Kinome-wide selectivity screening for zilurgisertib (compound 15)
“The kinome-wide selectivity of 15 was determined by using the DiscoveRx KINOMEscan platform to measure the binding affinities for approximately 450 kinases at 1 μM, and the results are summarized in the kinome dendrogram shown in Figure 3.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The kinases bound most strongly by 15 were ALK2 and ALK6, but ALK6 binding did not translate in any corresponding ALK6 inhibitory activity in the mobility shift assay (see Table 2). Beyond the BMP receptor kinase family, 15 interacted with only 11 kinases (20–50% of control), highlighting its supreme selectivity for ALK2 (also see the Supporting Information).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Role of ALK2 in bone and iron regulation
Pharmacodynamics
Cardiac electrophysiology
“As both studies indicated a dose‐dependent effect of zilurgisertib on heart rate, individualized QT correction (QTcI) was used as the primary endpoint for QTc analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No significant relationship between zilurgisertib plasma concentration and change in QTcI was identified; zilurgisertib did not have a clinically relevant effect on QTc prolongation. QT effect >10 ms could therefore be excluded within the dose range studied (up to 300 mg BID). No clinically meaningful effects on cardiac conduction (PR and QRS intervals) or any categorical PR or QRS outliers were observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Suppression of heterotopic ossification in a mouse model
“Zilurgisertib fully suppresses HO in a pediatric mouse model of injury-induced FOP and therefore holds great potential as a novel targeted disease-modifying therapy for FOP.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Compound 15 (zilurgisertib) was tested at four doses administered orally bid for 6 weeks in a pediatric FOP model of injury-induced HO following postnatal induction of expression of the ALK2[R206H] human FOP mutation (Alk2(R206H); Rosa26-CreERT2 compound heterozygous mice).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Radiographic imaging revealed dose-dependent potent suppression of heterotopic bone formation and corresponding preservation of joint mobility after the 6 week treatment period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The lowest tested dose of 2 mg/kg bid potently reduced HO formation and fully maintained joint mobility. Complete prevention of ankylosing heterotopic bone formation was observed at bid doses ≥5 mg/kg.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Threshold pharmacokinetic/pharmacodynamic relationship for heterotopic ossification suppression
“This consistently strong efficacy observed across all dose levels suggests an atypical pharmacokinetic/pharmacodynamic (PK/PD) relationship, in which the drug merely needs to achieve a threshold level of target engagement to trigger a durable, disease-modifying effect on heterotopic bone formation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Iron parameters in participants with FOP
Pharmacokinetics
Absorption
“Zilurgisertib was rapidly absorbed, with median time to maximum plasma drug concentration (Cmax) of 2.0–4.1 h post-dose. Zilurgisertib exposure was more than dose proportional after single and multiple doses over the dose range tested, suggesting non-linear pharmacokinetics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effect of food
“No food effect was observed on zilurgisertib pharmacokinetics, with geometric mean ratio (90% confidence interval) Cmax and area under the plasma concentration–time curve values of 0.98 (0.91 to1.06) and 1.03 (0.97 to 1.10).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Elimination, metabolism, and excretion
“Plasma half-life values ranged from 22.8 to 31.4 h, supporting once-daily dosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Renal excretion under fasted conditions was 16% and 27% of total drug clearance with single and multiple doses, respectively; therefore, it was not the predominant pathway for zilurgisertib elimination.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effect of age, sex, race, and body weight
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Embryo-fetal toxicity
Adverse reactions occurring in 10% or more of participants through Week 24
Adverse reactions occurring in fewer than 10% of participants
Laboratory findings: serum iron, hemoglobin, and transferrin saturation
Nonclinical hepatic findings and carcinogenic potential
Mutagenicity and fertility
Adverse events in healthy participants in the phase 1 studies
“In total, TEAEs were reported for 28 participants (31%) during the SAD study [zilurgisertib, n = 23 (33%); placebo, n = 5 (24%)] and 32 participants (41%) during the MAD study [zilurgisertib, n = 27 (46%); placebo, n = 5 (25%)]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No dose-limiting toxicities were observed and no deaths occurred during either study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two participants withdrew from the MAD study due to TEAEs (tachycardia, n = 1; hypersensitivity, n = 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Special populations
Pregnancy
Females of reproductive potential
Pediatric patients aged 12 to 16 years
Renal impairment
“Compared with matched controls, GMRs (90% CIs) for Cmax and AUC0‐∞ were as follows: mild renal impairment, 0.92 (0.64–1.34) and 0.98 (0.77–1.24); moderate, 1.22 (0.92–1.63) and 1.64 (1.28–2.10); severe, 1.00 (0.74–1.35) and 1.70 (1.33–2.16), respectively. Among participants with ESRD, values were the following: before haemodialysis, 1.17 (0.91–1.49) and 1.47 (1.15–1.88); after, 1.32 (1.00–1.75) and 1.68 (1.29–2.19), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our results indicate zilurgisertib dose adjustment is not required in patients with mild renal impairment or mild to moderate hepatic impairment. However, dose adjustment may be needed in those with moderate to severe renal impairment, ESRD undergoing haemodialysis, or severe hepatic impairment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatic impairment
“Among participants with hepatic impairment, values were as follows: moderate, 1.06 (0.80–1.42) and 1.13 (0.93–1.38); severe: 1.36 (1.05–1.76) and 1.25 (1.06–1.48), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Zilurgisertib exposure was unchanged with mild renal or moderate hepatic impairment, but increased by 30%–70% with moderate or more severe renal impairment and by 25% with severe hepatic impairment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Drug/Drug, drug/disease interactions
Effects of other drugs on zilurgisertib
Strong CYP3A4 inhibitors
“Participants in Cohort 1 (n = 18) received zilurgisertib 100 mg on Days 1 and 10 and itraconazole 200 mg once daily on Days 6-13.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“With the concomitant administration of itraconazole, the geometric mean maximum plasma drug concentration (Cmax) and area under the concentration-time curve from time 0 to infinity (AUC0-inf) of zilurgisertib increased by 1.28- and 2.13-fold, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
CYP3A4/5 estimated to account for about half of zilurgisertib clearance
“Assuming itraconazole completely inhibited CYP3A4/5 activity and had no effect on the bioavailability of zilurgisertib, CYP3A4/5 is therefore estimated to be responsible for approximately 53% of the overall clearance of zilurgisertib.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In addition to CYP3A4/5 inhibitors, itraconazole and hydroxy-itraconazole are also P-glycoprotein (P-gp) inhibitors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
More potent strong CYP3A4 inhibitors may increase exposure more than itraconazole did
“Strong CYP enzymes are known to vary in their magnitude of inhibition.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“such as ritonavir and ketoconazole, may cause even larger increases in its exposure than the approximately 2-fold effect seen here.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This may require even greater zilurgisertib dose reductions, and coadministration of zilurgisertib with these drugs may not be appropriate.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mild and moderate CYP3A4 inhibitors
Strong and moderate CYP3A4 inducers
“With the concomitant administration of rifampin, there was a 2.27- and 4.76-fold reduction in the geometric mean Cmax and AUC0-inf of zilurgisertib, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Zilurgisertib dose adjustment may be necessary with concomitant administration of strong CYP3A4 inhibitors, and coadministration of zilurgisertib with strong CYP3A4 inducers is not recommended.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Rifampin as a broad-spectrum, potent inducer represents a worst-case interaction
“Rifampin is the most potent inducer of P-gp” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, the effect of rifampin on the zilurgisertib exposure in this study represents a worst-case scenario for when zilurgisertib is coadministered with a CYP3A4/5 inducer.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Given the significant decrease in zilurgisertib AUC (4.76-fold) when coadministered with rifampin, concomitant use of zilurgisertib and rifampin should be avoided.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Effects of zilurgisertib on other drugs
MATE1 and MATE2-K substrates
Cytochrome P450 inhibition and induction in vitro
Dosing and administration
Dosage
Dosage modification with CYP3A4 inhibitors
Dosage modification for renal or hepatic impairment
No evidence found.
Administration
Administration with or without food
Access and distribution
Commercial availability, patient support program, and out-of-pocket cost
Mirum Access Plus services for patients and prescribers
Specialty pharmacy distribution of the manufacturer's approved medicines
Preapproval compassionate use and continued access for trial participants
Risk evaluation and mitigation strategy
No evidence found.
Co-prescribed/Concomitant therapies
Review of concomitant medications and supplements
Concomitant use with other FOP therapies
No evidence found.
Effect of zilurgisertib on quality measures
No evidence found.
Product comparison
Summary: products approved or in development for fibrodysplasia ossificans progressiva
Three products are approved by the Food and Drug Administration for fibrodysplasia ossificans progressiva, and each acts at a different point in the signaling pathway driven by the gain-of-function ACVR1 (ALK2) variant. Zilurgisertib is an oral ALK2 kinase inhibitor given as 100 mg once daily to patients aged 12 years and older. Palovarotene is an oral retinoic acid receptor gamma agonist given as 5 mg daily with a 12-week 20/10 mg flare-up regimen (weight-based below age 14), labeled for females aged 8 years and older and males aged 10 years and older. Garetosmab-grts is an intravenous activin A antibody given as 10 mg/kg every 4 weeks, labeled for adults only.
The pivotal evidence differs in design and endpoint. Zilurgisertib was compared with placebo in 63 participants for 24 weeks, with total new HO volume (which includes expansion of existing lesions) of −3.2 cm³ versus +24.6 cm³ (Hodges-Lehmann difference −15.8 cm³). Palovarotene was studied in a single-arm trial of 97 participants against an external natural history control of 101 untreated participants, with annualized new HO volume of 9.4 versus 20.3 cm³/year; the trial's prespecified, square-root transformed primary analysis at this interim analysis did not show a statistically significant difference from the control, and the reported reduction rests on post hoc analyses using non-transformed volumes. Garetosmab-grts was compared with placebo in 63 adults for 56 weeks, with 90% and 94% reductions in the number of new HO lesions at 10 mg/kg and 3 mg/kg; its difference in new HO volume was not statistically significant by the prespecified test.
All three labels contraindicate use in pregnancy. Palovarotene carries a boxed warning for embryo-fetal toxicity and premature epiphyseal closure in growing pediatric patients. Garetosmab-grts carries warnings for embryo-fetal toxicity, skin and soft tissue infections, and epistaxis. Zilurgisertib carries one warning, embryo-fetal toxicity. No head-to-head trial was identified, and each label states that adverse reaction rates from one drug's trials "cannot be directly compared to rates in the clinical trials of another drug". Among investigational products, fidrisertib (another ALK2 inhibitor) did not meet its primary endpoint in the 113-participant FALKON trial, and saracatinib and andecaliximab remain in phase 2 and phase 2/3 trials.
Zilurgisertib (Atebrioz): label profile
Palovarotene (Sohonos): label profile
Garetosmab-grts (Pasatru): label profile
Fidrisertib: phase 2 trial did not meet its primary endpoint
Saracatinib: phase 2a trial design
“The STOPFOP team identified AZD0530 (saracatinib) as a potent inhibitor of the ALK2/ ACVR1 -kinase which is the causative gene for this rare bone disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The STOPFOP trial is a phase 2a study. It is designed as a European, multicentre, 6-month double blind randomized controlled trial of AZD0530 versus placebo, followed by a 12-month trial comparing open-label extended AZD0530 treatment with natural history data as a control. Enrollment will include 20 FOP patients, aged 18–65 years, with the classic FOP mutation (ALK2 R206H).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Andecaliximab: phase 2/3 trial in pediatric and adult participants
Place of product in therapy
Disease description
Definition and etiology
Definition of fibrodysplasia ossificans progressiva
“Fibrodysplasia ossificans progressiva (FOP; MIM# 135100) is an ultra-rare, disabling, fully penetrant, autosomal dominant, genetic condition characterized by congenital malformations of the great toes and progressive, heterotopic ossification (HO) in specific anatomic patterns.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Flare-ups that often lead to HO are episodic and may be misdiagnosed as tumors; immobility is cumulative.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Genetic cause: gain-of-function variants in ACVR1, with R206H in about 97% of cases
“A common gain-of-function, missense pathogenic variant in activin receptor IA (ACVR1, also known as ALK2), encoding a bone morphogenetic protein (BMP) type I receptor, occurs in all sporadic and familial cases with a classic presentation of FOP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Approximately 3% of affected individuals have different pathogenic variants in ACVR1” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, all known individuals with FOP have gain-of-function, heterozygous, pathogenic variants in the gene encoding ACVR1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We mapped FOP to chromosome 2q23-24 by linkage analysis and identified an identical heterozygous mutation (617G-A; R206H) in the glycine-serine (GS) activation domain of ACVR1, a BMP type I receptor, in all affected individuals examined.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Classic and variant genotypes
Inheritance, de novo occurrence, and paternal age
“The vast majority of cases are due to the same alteration, R206H, and results from a spontaneous de novo mutation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A paternal age effect has been reported” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We found this mutation in all affected members of seven families, including all five families used for linkage analysis (Fig. 1c).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Investigation of sporadic cases of FOP with unambiguous clinical features showed the presence of the identical de novo mutation in 32 of 32 cases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 617G-A nucleotide mutation was not found in any of 159 unaffected individuals (112 unrelated controls and 47 clinically unaffected family members).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Genetic and environmental determinants of phenotype
Epidemiology
Incidence of Fibrodysplasia ossificans progressiva
Birth frequency derived from the French national prevalence estimate
Detectability before birth and effect of paternal age on future incidence
“Another question is whether FOP prevalence may rise due to the trend toward an increased paternal age, a known risk factor for FOP as for other conditions due to single-mutation variation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“FOP is rarely detectable in utero.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Population-based annual incidence
No evidence found.
Prevalence of Fibrodysplasia ossificans progressiva
United States: minimum prevalence of 0.88 per million, 2020
“After deduplication, 373 unique patients were identified in the United States, 294 of whom who were not listed as deceased in any list.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the application of the survival probability, it is estimated that 279 of these patients were alive on the prevalence date (22 July 2020). An adjusted prevalence of 0.88 per million US residents was calculated” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study suggests that the prevalence of FOP is higher than the often-cited value of 0.5 per million.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Taking into account the limitations described above, we report an estimated minimum prevalence of 0.88 per million individuals (1 in 1.14 million people) living in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this study, 11% (n = 31) of patients were 0 to < 10 years, compared to 23% (n = 65) in the ≥ 10 to < 20 years group, and 24% (n = 67) in the ≥ 40 years group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
France: capture-recapture estimate of 1.36 per million, 2012
“Using a capture-recapture methodology to adjust the crude number of patients identified in both data sources, 89 FOP patients were identified, which results in a prevalence of 1.36 per million inhabitants (CI95% = [1.10; 1.68]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Previous studies in Spain and the United Kingdom estimated FOP prevalence at about one case per two million population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
France: national rare disease registry estimate of 1.39 per million, 2020
Apparent prevalence by world region in patient organization databases
“The apparent prevalence of registered and confirmed FOP patients varied substantially from approximately 0.65 per million in North America and 0.47 per million in Western Europe to approximately 0.27 per million in Latin America, 0.05 per million in Africa, to nearly 0.04 per million in the Asia–Pacific region” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Number of known individuals in the United States and worldwide
Natural history, survival, and mortality
Onset in childhood and cumulative disability
“Most children with FOP develop episodic, painful, inflammatory soft tissue swellings called flare-ups during the first decade of life. While some flare-ups regress spontaneously, most transform soft connective tissues into mature heterotopic bone through a process of endochondral ossification.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most patients with FOP are confined to a wheelchair by the third decade of life and require lifelong assistance with activities of daily living. The median estimated life expectancy is 56 yr. Death often results from complications of thoracic insufficiency syndrome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prospective 36-month natural history study: flare-ups and new heterotopic ossification
“In total, 114 individuals participated; 33 completed the study (mean follow up: 26.8 months). Median age was 15.0 (range: 4-56) years; 54.4% were male. During the study, 82 (71.9%) individuals reported 229 flare-ups (upper back: 17.9%, hip: 14.8%, shoulder: 10.9%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Results from individuals receiving standard care for up to 3 years in this natural history study show the debilitating effect and progressive nature of FOP cross-sectionally and longitudinally, with greatest progression during childhood and early adulthood.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Imaged flare-ups with new heterotopic ossification at Day 84
Imaged flare-up frequency by age group
“A total of 52 flare-ups in 40 (35.1%) individuals were imaged (Supplement 2A). The proportion of individuals with ≥1 imaged flare-up was highest in the 2 to <8 years age group (47.1%) and lowest in the 25 to 65 years age group (25.9%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Functional and physical function scores over 36 months
“At baseline, mean CAJIS total score was 11.8 (SD = 7.0) points and mean FOP-PFQ percentage of the worst total score was 46.3% (SD = 28.1%); small increases were observed from baseline to Month 36 (1.6 points and 7.3%, respectively; Supplement 3A and B).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Baseline cross-sectional phenotype: HO volume and function increase with age
“Findings from 114 subjects (age range 4 to 56 years) were evaluated. While subject age was significantly (p < 0.0001) correlated with increased CAJIS (r = 0.66) and FOP-PFQ scores (r = 0.41), the estimated mean increases per year (based on cross-sectional average changes over time) were small (0.47 units and 1.2%, respectively). There was also a significant (p < 0.0001) correlation between baseline age and HO volume (r = 0.56), with an estimated mean increase of 25,574 mm3/year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anatomic progression and progression without flare-ups
“Onset of FOP usually occurred first in the neck and upper back, and with the exception of the jaw, progressed from axial to appendicular regions (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most body regions were affected before the third decade of life (Figure 2c).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Almost half of all patients (46.9%; 230/490) reported disease progression without flare-up symptoms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical staging
“Based on assessment of FOP features in seven areas, it is possible to assign five clinical stages.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Assessments of these features assign an individual with FOP to early/mild, moderate, severe, profound, or late-stage disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Median lifespan and causes of death in the international FOP community
“Sixty deaths (thirty male and thirty female patients) were reported in the fibrodysplasia ossificans progressiva community during a thirty-three-year-period. For all sixty patients, the median age at the time of death was forty years (range, three to seventy-seven years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median lifespan estimated from the 371 individuals in the international fibrodysplasia ossificans progressiva community who were alive and the sixty who had died was fifty-six years (95% confidence interval, fifty-one to sixty years). The most common causes of death in patients with fibrodysplasia ossificans progressiva were cardiorespiratory failure from thoracic insufficiency syndrome (54%; median age, forty-two years) and pneumonia (15%; median age, forty years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Survival compared with matched controls in France
“Overall survival was significantly worse in individuals with FOP vs the control group (p < .0001; Figure 4). Seven deaths were reported in the 77 individuals with FOP, and 8 deaths were reported in the 769 individuals without FOP. The mean (SD) age at death for individuals with FOP and controls was 50.4 (20.9) yr and 63.1 (18.3) yr, respectively (p = .2239).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of reported mortality
“Ten of the 32 publications reported the number of deaths within the study cohorts” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, none of the studies calculated annual mortality rates or contextualized the number of deaths observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most frequently reported causes of death, as determined by the investigators’ medical records review, were cardiovascular or cardiorespiratory issues, pneumonia, and trauma resulting from a fall.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pathophysiology
Constitutive and ligand-hyperresponsive ACVR1 signaling
Aberrant responsiveness of mutant ACVR1 to activin A
“We unexpectedly found that this mutation rendered ACVR1 responsive to the activin family of ligands, which generally antagonize BMP signaling through ACVR1 but cannot normally induce bone formation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When Acvr1[R206H] expression was induced, mice developed HO resembling that of FOP; HO could also be triggered by activin A administration in this mouse model of FOP but not in wild-type controls. Finally, HO was blocked by broad-acting BMP blockers, as well as by a fully human antibody specific to activin A.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Here, by using FOP patient-derived induced pluripotent stem cells (FOP-iPSCs), we report a third mechanism, where FOP-ACVR1 abnormally transduces BMP signaling in response to Activin-A, a molecule that normally transduces TGF-β signaling but not BMP signaling.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Endochondral sequence of heterotopic bone formation
Role of inflammation and triggers
“depletion of mast cells or macrophages impairs injury-induced HO in Acvr1[R206H/+] mice and reduces HO volume by <50% with depletion of each cell population independently and ~75% with combined depletion of both cell populations” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Hypoxia and mTOR signaling amplify BMP pathway activity
“Hypoxia-inducible factor-1α (HIF-1α) integrates the cellular response to both hypoxia and inflammation and increases the intensity and duration of BMP signaling in FOP. Inhibition of HIF-1α by genetic or pharmacologic means restores BMP signaling to normoxic levels in human FOP cells and profoundly reduces HO in a constitutively active Acvr1[Q207D/+] mouse model of FOP” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“a mechanistic target of rapamycin (mTOR) signaling upstream of HIF-1α was identified as a critical pathway for hypoxia sensing in the aberrant chondrogenesis of FOP and unveiled a crucial role of the mTOR axis in FOP pathogenesis” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
ACVR1 as a therapeutic target
“The discovery of the genetic variants in ACVR1 that cause FOP established a critical milestone in understanding FOP, revealed a highly conserved therapeutic target in the BMP signaling pathway, and propelled the development of novel inhibitors of ACVR1-mediated BMP pathway signaling.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Guideline: clinical diagnosis with required genetic confirmation
“The diagnosis of FOP is clinical (malformed great toes and progressive HO) but requires genetic confirmation of a pathogenic ACVR1 gene variant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If FOP is suspected, all elective procedures such as surgeries, biopsies, and IM immunizations should be deferred until a definitive diagnosis is confirmed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Early clinical signs that prompt genetic testing
“Individuals will often present in their first decade of life with great toe malformations and lumps/swellings on the scalp, head, neck and/or back” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“FOP is the only condition with this combination of symptoms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
International survey: misdiagnosis in 87% and diagnostic delay of 4.1 years
“Incorrect diagnoses were given initially to 87% of individuals with FOP.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most common incorrect diagnosis was cancer (32%). The mean period from the onset of symptoms to correct diagnosis was 4.1 years, and the median number of physicians consulted before the correct diagnosis of FOP was 6. For 67% of patients, unnecessary invasive procedures (biopsies) were performed; 68% received inappropriate therapies. Forty-nine percent of all patients reported permanent loss of mobility resulting from invasive medical interventions that caused posttraumatic ossification.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
FOP Registry: time to diagnosis and number of providers consulted
“Data from the FOP Registry (as of December 2020) show that on average, individuals with FOP receive a correct diagnosis around 1.5 years following symptom onset, with over 50% of individuals initially misdiagnosed” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“According to recent FOP Registry data, individuals with FOP receive a correct diagnosis after seeing an average of 3.3 HCPs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Initial evaluation and diagnosing provider in the IFOPA registry
“Most patients consulted a pediatrician (27.4%) or an orthopaedic physician (12%) for their initial diagnostic evaluation, and most often received their correct diagnosis from a geneticist (18.1%) [data not shown].” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
China: misdiagnosis in 78.8% and iatrogenic harm in 62.7%
“Up to 78.8% of patients would have been misdiagnosed at least once, with tumors (40.9%) being the most common misdiagnosed condition. 62.7% of patients received iatrogenic harm, with surgeries (26.9%), biopsies (25.4%), and punctures (17.9%) being the most common iatrogenic injuries experienced.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Only 23.9% of patients received a correct diagnosis at their initial hospital visit (Table S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age at diagnosis
“Mean age at FOP diagnosis was 6.9 years (range: birth to 63 years); the median age was 5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean age at diagnosis was 10 years, and above 18 years for 14.9% of the patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the age group at index date, the mean (SD) age at diagnosis was 2.43 (2.34) yr for individuals aged <10 yr at index date, 4.64 (4.59) years for individuals aged 10-20 yr, 5.91 (4.90) years for individuals aged 20-30 yr, and 9.29 (8.29) yr for individuals aged ≥30 yr (p = .0189 for the difference between age at diagnosis for age groups).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age at symptom onset and age at diagnosis in the IFOPA registry
Pediatric cohort: biopsy before referral and scalp nodules as an early sign
“Four patients underwent biopsy prior to referral to our institution. One was coincidentally associated with Ewing sarcoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Scalp nodules could be a transient finding with spontaneous regression and were an early manifestation in 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical presentation - signs and symptoms
Congenital skeletal malformations: great toes and other anomalies
Flare-ups: presenting symptoms, frequency, and triggers
“Major symptoms experienced during a flare-up included swelling (93.1%; 429/461), pain (86.3%; 398/461), decreased movement (78.5%; 362/461), stiffness (72.9%; 336/461), and warmth (15%; 313/461) [Figure 3a].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“About 71% (341/460) reported at least one flare-up in the previous 12 months. Overall, patients reported an average of 1.9 ± 0.1 flare-ups in the preceding 12 months (median 1.0; range of 0 to 7)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Intramuscular immunization was the cause of a flare-up in 25.1% (115/459), which led to bone formation in 84.3% (97/115) of these patients. As many as 61% of all flare-ups occurred spontaneously.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Heterotopic ossification: anatomic pattern
Joint immobility and loss of function after flare-ups
“Among all responders, 96.4% (479/685) reported at least one body region with partial or limited movement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Almost half of survey participants reported that their last flare-up resulted in at least a 50% reduction of mobility around a joint, with 15% reporting a complete loss of movement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pain: during and outside flare-ups
“We observed that although moderate to severe pain (≥4, 0 to 10 pain scale) was commonly associated with flare‐ups (56% to 67%), surprisingly, 30% to 55% of patients experienced similar pain levels during non–flare‐up states.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Chronic pain syndromes are common in FOP and may be related to neuropathies (eg, entrapment, nerve damage, allodynia), musculoskeletal origin (eg, back pain, myofascial pain), inflammation, or mechanical/compressive causes (eg, from expanding HO, especially late in the course of a flare-up).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Respiratory: restrictive chest wall disease and thoracic insufficiency
“Restrictive pulmonary function, identified by TLC or suspected by FVC, was found in all, but one, patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In conclusion, restrictive pulmonary function was found in the majority of patients already at an early age.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hearing: conductive hearing impairment
“Conductive hearing impairment is common in FOP through various mechanisms. Fibrodysplasia ossificans progressiva patients should be screened in childhood by audiometry for hearing impairment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the literature, prevalence is reported between 30.8% and 42%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All the patients developed at least a mild hearing loss.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Jaw ankylosis and nutrition
Neurological: headache and neurological symptoms
“Patients with FOP have reported a higher incidence of neurological symptoms, including pain both during and after an FOP flare-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Some individuals with FOP report chronic headaches.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Psychological: anxiety, depression, and irritability
“In those patients reporting pain levels of ≥4, 45% to 74% of patients report experiencing anxiety, depression, or irritability, with 36% to 48% reporting emotional problems during no to mild pain states.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
System-based symptom burden in the IFOPA registry
“Auditory complaints were the most common and included hearing loss and earaches/drainage. Sleep problems, especially poor sleep quality, and increased sleep latency, were the next most common complaints. Among pulmonary issues reported, difficulty breathing, cough, and respiratory infection were the most prominent conditions. Dermatologic complaints included rash and ulcers. Abdominal pain was the most prevalent gastrointestinal complaint, followed by reflux symptoms and nausea. The most prevalent neurological symptoms were headaches, paresthesias, and neuropathic pain. Flank pain and nephrolithiasis were the most frequent renal/urologic concerns. Menstrual abnormalities were the most common endocrine problem and heart palpitations the most common cardiac issue.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Long-term morbidity
Comorbidities by organ system in a systematic review
“In our SLR, data on FOP comorbidity were extracted from 27 of the included studies, encompassing 73 distinct diseases and disorders. The three organ systems most affected by the conditions studied were, in order of severity, the cardiovascular (40–70%), skeletal (50–65%), and respiratory (20–42%) (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Falls and fractures were prevalent, affecting roughly 50% of the 260 patients with FOP collectively included in three of the eight studies reviewed” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comorbidities compared with matched controls in France
“Almost one-quarter (22.9%; n = 16) of individuals with FOP had a CCI score ≥ 1 compared with 3% (n = 21) of controls (Table 3). Notable long-term comorbidities occurred significantly more frequently among individuals with FOP compared with the control group and included neurological and muscular disorders (21.4% vs 0.9%; p < .0001), malignant tumors (4.3% vs 0.9%; p = .0407), inherited metabolic diseases (4.3% vs 0%; p = .0007), systemic disease (2.9% vs 0.1%; p = .0231), and ankylosing spondylitis (2.9% vs 0%; p = .0082; Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Disability severity by age
“According to these definitions, approximately half of all individuals with FOP (55.7%; n = 39/70) had a high severity of disability, whereas 37.1% (n = 26/70) had no identified severity between 2008 and 2019.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Developmental arthropathy and degenerative joint disease
Hospitalization in the 12 months before registry enrollment
Hospitalizations in a 10-year Swiss six-disease cohort
“Of the 2875 hospitalizations, 1146 were attributed to XLH, 925 to OI, 437 to FD, 219 to ACH, 87 to PHP, and 62 to FOP (Figure 1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adult hospitalizations predominated in individuals with XLH (95.2%) and FOP (90.3%), while pediatric hospitalizations were common in individuals with ACH (52.1%) and OI (41.1%). Female sex was more prevalent in hospitalizations of individuals with ACH (63%) and FOP (61%), and similarly distributed in the other studied rare bone disease groups and the general population (48%-57%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Comorbidity burden and lifelong hospitalization pattern in fibrodysplasia ossificans progressiva
“Individuals with FD and ACH showed comorbidity patterns broadly comparable to the general population. Estimates for PHP and FOP were variable due to small sample sizes, with a possible trend toward a higher comorbidity burden.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Hospitalizations in PHP and FOP occurred throughout the lifespan, reflecting lifelong healthcare need, although clear trends were limited by small sample sizes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Burden of Fibrodysplasia ossificans progressiva
Humanistic burden and health-related quality of life
EQ-5D-5L and PROMIS Global Health in an international burden of illness survey
PROMIS Global Health Scale scores by age in the IFOPA registry
“The mean total scores for age groups 0– < 9 years, 9–15 years, and > 15 years were 25.4, 26.6, and 32, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There is a strong, statistically significant association between the total PROMIS Global Health score and the number of anatomic sites subjectively reported as being affected by HO.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Validation of the FOP Physical Function Questionnaire
“Factor analysis confirmed a two-factor solution: Mobility and Upper Extremity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The FOP-PFQ was demonstrated to be a reliable, valid measure that may be responsive to change in individuals with FOP, although some results were inconclusive for pediatric versions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Development and factor structure of the FOP-PFQ
“Development of the adult and pediatric versions of the FOP-PFQ involved a literature review, two iterative phases of qualitative work with participants, and clinical expert review.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The comprehensiveness, relevance, and understandability of the adult measure was evaluated throughout and resulted in the final 28-item questionnaire.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Initial exploratory factor analysis models based on retention of factors with eigenvalues of ≥1 suggested a two-factor solution (Factor 1: Upper Extremity function; Factor 2: Mobility function), which was confirmed by follow-up models that pre-specified two factors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Reliability of the FOP-PFQ
“The FOP-PFQ yielded high alphas and ICCs at Baseline and Month 12.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This indicates that FOP-PFQ scores were stable over the 1–3-week interval between questionnaires for individuals with no flare-ups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Convergent and known-groups validity of the FOP-PFQ
“Adult and pediatric FOP-PFQ scores were worse for individuals with worse physical function and correlated with other measures of physical function, supporting convergent validity (Table 3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“FOP-PFQ scores were significantly worse in groups of individuals with more severe disease, supporting known-groups validity, suggesting the instrument performs effectively as a measure of severity and potentially disease progression over time.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Correlation of HO volume with physical function
Pain severity and quality of life in the FOP Registry (PROMIS-based)
EQ-5D health utility by age in China
“The average health utility values of patients < 8 and 8–15 years were 0.700 ± 0.163, 0.618 ± 0.202 measured by EQ-5D-Y. The utility values of patients ≥ 16 years were 0.221 ± 0.336 measured by EQ-5D-5L, significantly lower than the younger patients (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
France: annual healthcare expenditure 10 to 14 times higher than matched controls
“Mean total annual healthcare expenditure was more than 10 times greater in individuals with FOP than those without FOP from a societal perspective (largely driven by outpatient costs) and 14 times greater from a payer perspective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consultations with general practitioners and non-physician healthcare providers, hospitalizations, and use of medical devices and treatments were significantly greater in individuals with vs without FOP (p < .05 for all).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
France: costs by disability severity and age
“Mean total expenditures for individuals with no identified severity were €3152 compared with €11 820 for individuals with high disability severity level (p = .0002)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Outpatient costs were the only societal cost category to increase significantly with age (<10 yr, €1399; >30 yr, €7438; p = .0133).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Total societal costs were largely driven by outpatient costs, of which medical devices were the most expensive component (mean annual cost: €1761).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
China: annual cost per patient of USD 10,820, mostly indirect
“The average total annual cost was $10,820 ± 10,894, of which indirect and direct non-medical costs accounted for 75.2% ($8,134 ± 7,978) and 21.6% ($2,332 ± 7,374), respectively (Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the past year, up to 61.2% of patients had neither outpatient nor inpatient visits due to FOP. Only 14.9% of patients had hospital admissions, with an annual average of 1.8 ± 1.6 hospitalizations per patient.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: out-of-pocket cost of care by mobility level
Healthcare services and assistive devices used
In-hospital outcomes among FOP hospitalizations compared with matched controls in Switzerland
| Outcome | FOP hospitalizations | Matched comparators | Relative risk or change (95% CI) |
|---|---|---|---|
| Length of hospital stay, days, median (IQR) | “5.5 (3-13)”View highlighted excerpt for this quote | “3 (2-5.75)”View highlighted excerpt for this quote | “2.04 (1.58, 2.62)”View highlighted excerpt for this quote |
| ICU admission, n (%) | “10 (16.1)”View highlighted excerpt for this quote | “19 (6.1)”View highlighted excerpt for this quote | “2.63 (1.29, 5.38)”View highlighted excerpt for this quote |
| In-hospital mortality, n (%) | “1 (1.6)”View highlighted excerpt for this quote | “5 (1.6)”View highlighted excerpt for this quote | “1.00 (0.12, 8.41)”View highlighted excerpt for this quote |
| 30-day readmission, n (%) | “9 (14.5)”View highlighted excerpt for this quote | “18 (5.8)”View highlighted excerpt for this quote | “2.50 (1.18, 5.30)”View highlighted excerpt for this quote |
Economic impact of Fibrodysplasia ossificans progressiva on families
Caregiver time, burden, and career effects
Emotional impact on family members
Caregiver productivity loss in children and adolescents in China
“For patients aged < 8 years and 8–15 years, the main cost components arose from productivity loss in indirect costs incurred by caregivers totaling $7,409 ± 6,406 (52.4%) and $6,806 ± 8,367 (79.5%), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients aged < 8 and 8–15 years, 50% and 23.5% were suspended or absent from school respectively. Additionally, 40.6% of those aged ≥ 16 years were unemployed due to FOP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, a substantial 95.5% of patients relied on caregivers for caregiving.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
School accommodations for children
Economic impact of diagnostic testing
Cost and availability of ACVR1 genetic testing as a barrier
“The ability to provide a clinical diagnosis of FOP is particularly valuable for individuals living in regions where genetic testing is either not available or cost prohibitive. However, where available, genetic testing can also be beneficial, particularly for individuals with an atypical genetic mutation or for those who have great toe malformations without HO” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, there are also important ethical considerations over screening for a disease with no approved treatment, concerns over the risk of misdiagnosis based on clinical observation in newborns, and regulatory/cost-effectiveness barriers related to genetic testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recommendation for electronic health record prompts for ACVR1 testing
“And we recommend developing intelligent alert modules within electronic health record (EHR) systems to trigger FOP diagnostic prompts and recommendations for ACVR1 genetic testing based on symptom keywords such as'progressive joint stiffness'.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Price of ACVR1 genetic testing and cost of the diagnostic pathway
No evidence found.
Approaches to treatment
Current treatment options and standard of care
Retinoic acid receptor gamma agonists
Status of palovarotene in the international clinical guideline
“Palovarotene, an RAR -γ agonist, has been approved in the United States, Canada, UAE, Australia, and Russia but not approved in Europe.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Regulatory-approved medications have been approved by at least 1 regulatory authority (eg, US Federal Drug Administration, or FDA). Currently, only chronic and episodic use of palovarotene (Sohonos) has received limited regulatory approval.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Chronic and flare-up dosing regimen
Premature epiphyseal closure and growth monitoring
Mucocutaneous and bone adverse reactions
Prespecified and post hoc analyses of the phase 3 MOVE trial
“During the prespecified analysis at month 18 of the phase III MOVE trial (interim analysis 3; IA3), which represents the most complete dataset from this trial, no statistically significant difference was found in the mean volume of annualized new HO in patients treated with palovarotene in MOVE compared with untreated patients from the NHS, leading to a temporary suspension of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subsequent post hoc analyses showed that the mean annualized new HO volume was 54% lower in MOVE compared with the NHS (weighted linear mixed effects [wLME] analysis, p = .039), supporting the approval of palovarotene in patients with FOP in several countries.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Month-48 efficacy and safety of palovarotene
“Across 48 mo, mean annualized new HO volume was numerically lower (46.4%) in palovarotene-treated patients compared with untreated patients; however, this difference was not significant (nominal p = .0585).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The proportions of patients with new HO and number of affected body regions were similar in palovarotene-treated patients and untreated patients (significance not assessed); flare-up rates were consistent with published literature.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In 80 patients aged <18 yr in MOVE, palovarotene treatment occurred for a mean (SD) of 166.0 (75.2) wk; 24 (30.0%), all aged <14 yr, had premature physeal closure events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Refusal of marketing authorisation in the European Union
Regulatory review history in Canada and the United States
“Palovarotene was first reviewed and approved by the Health Canada in January 2022.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The FDA advisory committee voted 10 in favor and 4 against the evidence showing palovarotene to be effective for blocking new HO formation in FOP, and voted 11 for and 3 against the evidence showing that the benefits of palovarotene outweighed the risks for treating patients with FOP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prespecified square-root transformed analysis did not reach significance at interim analysis 3
“Prespecified futility criteria were met using this analysis method at IA2; however, following post hoc results obtained at IA2, Bayesian analysis of nontransformed data was reconsidered at IA3 when all patients had completed 18 months of follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At IA3, the prespecified Bayesian analysis fitted a 5% reduction in square-root transformed annualized volume of new HO in palovarotene-treated patients in MOVE versus NHS participants untreated beyond standard of care.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The post hoc Bayesian analysis fitted a 36% reduction in non-transformed mean annualized volume of new HO in palovarotene-treated patients compared with NHS participants (probability of any reduction in new HO: 99.4%) (Supplemental Fig. S6).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Comparability of MOVE and its external natural history control
“Baseline demographics and characteristics for the MOVE Principal Enrolled Population (N = 99) and NHS comparator population (N = 111) showed more individuals aged <18 years in MOVE (75/99 [75.8%]) than in the NHS (66/111 [59.5%]); the two populations were otherwise similar (Table 1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among these 39 patients who contributed data to both studies, mean annualized new HO volume was 54% lower with palovarotene compared with their prior phase receiving no treatment beyond standard of care in the NHS (Supplemental Fig. S7).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Activin A monoclonal antibodies
Phase 3 OPTIMA trial: new lesions and flare-ups
Warnings for infection and epistaxis
Phase 2 LUMINA-1 trial
“The primary efficacy end point in period 1 (total lesion activity by PET–CT) was not met ( P = 0.0741). As the development of new HO lesions was suppressed in period 1, the primary efficacy end point in period 2 was prospectively changed to the number of new HO lesions versus period 1. No placebo patients crossing over to garetosmab developed new HO lesions (0% in period 2 versus 40.9% in period 1; P = 0.0027).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Five deaths (5 of 44; 11.4%) occurred in the open-label period and, while considered unlikely to be related, causality cannot be ruled out.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline classification before approval
“Blocks Activin A signaling through mutant ACVR1/ALK2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Not applicable at Present time; Ongoing Phase III clinical trial” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Corticosteroids for flare-ups
Recommended prednisone regimen for acute flare-ups
“Class I medications can be considered for acute flare-ups involving the major joints of the appendicular skeleton. The immediate use of prednisone at a dose of 2 mg/kg/d (up to 100 mg) can be considered as a single daily dose for a maximum of 4 d. For maximum beneficial effect, the prednisone should be started within 24 h of the onset of a flare-up, which corresponds to the earliest phase of acute inflammatory infiltration into skeletal muscle. If the flare-up is more than 2 days old, prednisone is generally less effective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prophylaxis after injury and before procedures
“Corticosteroid prophylaxis is recommended for significant blunt muscle trauma, as prophylaxis for a potential flare or as treatment of an active flare. The usual recommended dose is prednisone 2 mg/kg/d per oral × 4 d, with a maximum dose of 100 mg/d.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Corticosteroid prophylaxis is recommended for dental and surgical procedures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Restrictions on axial flare-ups and chronic use
“Prednisone should generally not be used for flare-ups on the chest or trunk, as it is difficult to judge the exact onset of a new flare-up. Prolonged or chronic use of corticosteroids is of no benefit, is harmful systemically, and should not be considered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Submandibular flare-ups as a medical emergency
“Flare-ups of the anterior neck beneath the chin (submandibular) can compromise breathing and swallowing and should be considered a medical emergency. Submandibular flare-ups require early identification. Provide high-dose steroids immediately (Solumedrol 80 mg intravenously or Dexamethasone 15 mg intravenously).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nonsteroidal anti-inflammatory drugs and COX-2 inhibitors
Symptomatic role without evidence of flare-up prevention
“There is no definitive evidence that chronic treatment with COX-2 inhibitors or NSAIDs prevents or ameliorates flare-ups in FOP. However, COX-2 inhibitors or oral/topical NSAIDs may be helpful for symptomatic management of flare-ups and chronic arthropathy when corticosteroids are not indicated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Use after corticosteroids and associated precautions
“When prednisone is discontinued (or if a flare-up existing for more than 48 h is being considered for treatment), symptomatic treatment may be considered with a non-steroidal anti-inflammatory agent (NSAID). A COX-2 inhibitor can be used instead of a traditional NSAID ( Table 1 ). As with all NSAIDs, GI precautions should prevail. If long-term use of a COX-2 inhibitor is considered, serum liver and kidney function tests should be monitored.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Back and chest flare-ups
“Consider non-steroidal anti-inflammatory medications (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors (oral or topical) with assiduous gastrointestinal (GI) precautions. Use analgesics, muscle relaxants, and local applications of ice packs, as needed. Avoid narcotic analgesia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Off-label therapies
Guideline position on off-label medications
“Class II Medications can be considered on off-label use with caution, at the physician’s discretion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is no definitive evidence that these medications prevent or ameliorate HO after flare-ups in FOP. These medications may be considered for patients with severe, intractable FOP flare-ups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bisphosphonates
Case-series evidence for tofacitinib and canakinumab
“In an FOP case series by Nikishina et al. 2023, levels of IL-1RA decreased in 4/5 individuals (80%) and increased in 1/5 (20%), suggesting that at least part of the mechanism of action in FOP is related to suppression of inflammatory cytokines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In an FOP uncontrolled case series of 4 patients by Haviv et al. 2024, flare activity was reduced by 61%-89%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rapamycin: case reports without disease-modifying benefit
“Several recent studies in genetic mouse models of FOP support involvement of the mechanistic target of rapamycin complex 1 (mTORC1) pathway in the pathophysiology of FOP and propose the repurposed use of rapamycin, an inhibitor of mTORC1 signaling in clinical trials for the management of FOP.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“She was treated with rapamycin (1 mg/m[2] ) for three months with a desired rapamycin trough level between 7 and 13 μg/L. Despite the treatment regimen, there was no discernible improvement.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Following a minor rejection episode at age 10, cyclosporine was discontinued and rapamycin (sirolimus) was begun at a dose of 1–2 mg/m[2] (adjusted to therapeutic trough levels of 6–15 μg/L) for the next 18 years till the time of this report. Despite 18 years of daily rapamycin therapy, and episodic use of glucocorticoids, flare-ups and HO progressed spontaneously or following minor soft tissue trauma (Fig. 2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In both patients, FOP progressed despite the use of rapamycin.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Approaches with no role or that are contraindicated
“There is no evidence of efficacy with these agents. The use of these approaches is contraindicated in the management of FOP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The chronic use of antiangiogenic agents, calcium binders, colchicine, fluoroquinolone antibiotics, propranolol, mineralization inhibitors, PPAR-γ antagonists, and TNF-α inhibitors currently has no role in the management of FOP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Injury prevention and supportive care
Focus of present management
“However, present management is focused on early diagnosis, assiduous avoidance of injury and iatrogenic harm, symptomatic amelioration of painful flare-ups, optimization of residual function, and monitoring and treating co-morbidities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Avoidance of flare-up triggers, biopsies, and elective surgery
“The prevention of flare-ups and heterotopic bone formation involves multimodal approaches. This includes the recognition and avoidance of known causes of flare-ups: contact sports, soft tissue injuries, blunt muscle trauma, muscle fatigue, muscle stretching, IM injections and immunizations, biopsies, removal of heterotopic bone, all non-emergent surgical procedures, and viral illnesses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If FOP is suspected, all elective procedures such as surgeries, biopsies, and IM immunizations should be deferred until a definitive diagnosis is confirmed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Avoid surgery, except in emergencies. Always avoid surgery to remove heterotopic bone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immunization route and venous access
“Immunization by subcutaneous administration is recommended for all vaccines that can be administered by that route. Avoid all IM immunizations and intranasal influenza immunizations with live vaccines as they may precipitate flare-ups of FOP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Central lines, PICC lines, and arterial punctures may cause HO and should be avoided unless critical for the patient’s medical management.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anesthesia precautions
“An expert anesthesiologist experienced in general anesthesia for FOP patients must be consulted pre-operatively in all cases. If general anesthesia is required, an awake intubation by nasotracheal fiber-optic technique should be performed because of cervical spine fusions, jaw motion limitations, sensitive airway, and risk of inducing an obstructing neck flare-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Physical and occupational therapy and assistive care
“Passive range of motion to restore or improve joint range of motion is strictly prohibited. An assessment of ambulatory aids may be indicated. Warm water hydrotherapy may be helpful.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Perform periodic OT evaluations for assistive devices, as activities of daily living are likely to change over time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Singing, swimming, and incentive spirometry are strongly encouraged to maintain lung function.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of current therapies
Summary: limitations of therapies available before and after the 2026 approvals
The international clinical guideline states that no medication has been proven to alter the natural history of fibrodysplasia ossificans progressiva and that its evidence-based statements are "generally moderate to low". Its management rests on injury avoidance and symptomatic treatment of flare-ups; corticosteroids are limited to 4-day courses started within 24 hours of onset, and no definitive evidence shows that NSAIDs, COX-2 inhibitors, bisphosphonates, or off-label agents prevent flare-ups or heterotopic ossification. The guideline predates the approvals of garetosmab-grts (August 2026) and zilurgisertib (September 2026) and lists both as investigational Class III agents.
Until 2026, palovarotene was the only approved therapy. Its approval rested on post hoc analyses against an external natural history control after the prespecified month-18 analysis showed no statistically significant difference, and at month 48 the 46.4% lower annualized new HO volume was not significant (nominal p = .0585). Premature physeal closure occurred in 24 of 80 participants younger than 18 years (30.0%), all younger than 14 years, and the European Medicines Agency refused marketing authorisation. Garetosmab-grts is labeled for adults only, requires intravenous infusion every 4 weeks, and did not show a statistically significant difference in new HO volume. Zilurgisertib is not established in patients younger than 12 years. No approved therapy is labeled for females younger than 8 years or males younger than 10 years. Fidrisertib, a second ALK2 inhibitor, did not meet its primary endpoint in 113 participants.
No medication proven to alter the natural history
Strength of the evidence behind guideline recommendations
“As FOP is an ultra-rare condition, evidence-based statements are generally moderate to low.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the absence of clear evidence-based research from controlled clinical trials, it is difficult to advocate a particular therapy with enthusiasm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Standard of care limited to symptom management, and constraints in growing patients
“The current standard of care (SoC) for FOP is limited to symptom management and flare-up prevention.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This may limit the ability to treat growing patients with palovarotene and thus highlights the need for additional disease-modifying therapies for these individuals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Multiple pathway nodes under investigation, with no approach yet established as most effective
“The development of therapies for FOP have focused on targeted inhibition of the ACVR1 receptor, ACVR1 ligands, BMP pathway signaling, preosseous chondrogenic anlagen of HO, and inflammatory triggers of disease activity (Figure 1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Currently, it is too early to determine which one of these approaches or combinations of approaches will be most effective in FOP, and all are being studied intensively in preclinical and/or clinical studies” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Place in treatment, anticipated use, and care setting
Summary: anticipated position of an oral ALK2 inhibitor
Zilurgisertib is the second oral product and the third product overall approved for fibrodysplasia ossificans progressiva. It is taken once daily at home, with or without food, and tablets may be crushed into water, juice, apple sauce, or yogurt for patients who cannot swallow them. Its labeled population (12 years and older) includes adolescents aged 12 to 17 years, for whom garetosmab-grts is not labeled, and growing adolescents, for whom the palovarotene label carries a boxed warning for premature epiphyseal closure. Garetosmab-grts, by contrast, is given by intravenous infusion over 60 minutes every 4 weeks using an infusion pump. The international clinical guideline has not been updated since the 2026 approvals and classifies zilurgisertib as an investigational Class III agent. Zilurgisertib is expected to be commercially available in October 2026 through the Mirum Access Plus patient support program. No source identified in this review defines the order in which the three approved products should be used.
Intravenous administration of the activin A antibody
Commercial availability and investigator statement on adolescents
Guideline classification before approval
“Class III Agents are compounds under development, being tested in clinical trials, and are not yet available for general use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ACVR1/ALK2 Signal Transduction Inhibitor, STI (Zilurgisertib; INCB000928) [Incyte; PROGRESS]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Heterogeneity of treatment effect
Variability of disease course among individuals
“However, there is great variability among individuals in terms of course and severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although there are common physical features shared by every person who has FOP, there are differences among individuals that may alter the potential benefits or risks of any medication or class of medications discussed here.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ACVR1 variant and eligibility in the pivotal trial
Age and disease severity of the enrolled population
Safety and exposure by age group
Age-dependent risk with the retinoic acid receptor gamma agonist
“In MOVE, the 80 patients aged <18 yr (age range: 4-17 yr) received palovarotene for a mean (SD) of 166.0 (75.2) wk. Of these, 24/80 (30.0%) had clinical events consistent with PPC, all of which occurred in those aged <14 yr” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Care management intervention strategies
Pregnancy testing and contraception
Medication and food interaction review
Coordination with FOP specialists and clinical trial investigators
“Each patient should have a primary physician who is willing to consult with an FOP expert and help coordinate a local care team.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ask if patient is enrolled in any FOP Clinical Trials and communicate with principal investigator and regional FOP specialist.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prescriber education and growth monitoring for palovarotene
Other product development or post-marketing obligations required by the FDA
Postmarketing requirements and commitments in the approval letter
No evidence found.
Pediatric development in children younger than 12 years
Carcinogenicity studies not conducted before approval
European marketing authorisation application
Ongoing post-approval monitoring
Open-label extension of the pivotal trial
Iron parameters during long-term treatment
Pregnancy exposure registry
No evidence found.
Post-marketing registry for the retinoic acid receptor gamma agonist
Expected outcomes of therapy
Summary: outcomes reported for zilurgisertib
In the 24-week double-blind period of PROGRESS, total new HO volume (new lesions plus expansion of existing lesions) decreased by a mean of 3.2 cm³ with zilurgisertib and increased by 24.6 cm³ with placebo. The registered primary endpoint, the proportion of participants with new HO lesions, was 1 of 32 (3.1%) with zilurgisertib and 5 of 30 (16.7%) with placebo (P=0.0986). Mean volume of new lesions was 0.003 cm³ with zilurgisertib and 6.57 cm³ with placebo, and mean annualized new flares were 2.34 and 4.55. No new lesions were reported in either group from Week 24 to Week 48 of the open-label extension. The effect of these radiographic changes on joint function, mobility, and survival has not been reported, and no consensus threshold defines a clinically meaningful reduction in new HO volume.
Labeled efficacy at Week 24: total new HO volume
Registered primary endpoint and new lesion volume at Week 24
Durability through Week 48 of the open-label extension
Relation of new HO volume to function
“Currently, there is no consensus on a threshold for a clinically meaningful reduction in new HO volume in patients with FOP, and this warrants further research.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“reducing the volume of new HO over time may help slow the progression of functional disability, and preventing even small volumes of new HO in certain joints may be crucial for maintaining patients’ mobility and quality of life.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Disease course without disease-modifying therapy
“Most patients with FOP are confined to a wheelchair by the third decade of life and require lifelong assistance with activities of daily living. The median estimated life expectancy is 56 yr. Death often results from complications of thoracic insufficiency syndrome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote